As a company committed to operating in low resource settings, evidenced by a recent major grant from the Bill & Melinda Gates Foundation for maternal health monitoring, Sibel is proud of its work in validating the accuracy of its pulse oximeter across a wide range of skin tones.

“Our strategic partners from pharmaceutical companies to major medical technology companies are already spinning out amazing software applications leveraging our wearables and SDK in as little as 1 week. We know we can’t make software for every application—and with these FDA-clearances we won’t have to. We want to enable other creators to have access to continuous vital signs from our FDA-cleared sensors wherever they see a clinical need,” says Steve Xu MD, CEO and co-founder of Sibel Health. In August 2023, Sibel announced FDA-clearance for its complete monitoring system that includes both the ANNE^® Chest and Limb sensors for continuous vital signs assessments.